Abstract
PurposeARFs are a family of Ras-related GTP binding proteins, ARF6, in particular, is implicated in cancer invasion and metastasis. However, the role of ARF proteins in prostate cancer have yet to be investigated.MethodsImmunohistochemical staining for ARF6 was performed on a prostate cancer tissue microarray with patient matched normal specimens.ResultsAntibody staining was significantly over-expressed in prostate cancer patient samples compared to normal patient tissue and a trend towards increased staining intensity in cancer samples with Gleason scores of 8 and above (metastatic disease).ConclusionDue to high homology between members of the ARF family we could not determine if ARF 6 was the only ARF over-expressed in the prostate cancer samples. However, we are the first to show that ARF-GTPases are over expressed in prostate cancer which provides further insight into the molecular biology of prostate cancer.
Highlights
Prostate cancer (PCa) is the most common cancer in men in the UK with over 40,000 cases diagnosed each year (CancerResearchUK 2015)
Immunohistochemistry To determine whether an increased expression of ARF6 protein maybe be found in prostate cancer patients we performed immunohistochemistry (IHC) on a commercially available prostate cancer tissue microarray (TMA) (AccuMax array, ISU ABXIS, Seoul, Korea)
Immunohistochemical analysis using a commercial antibody to ARF6 showed a significant increase in the observed sum of staining intensity and distribution between cancer and matched normal samples (P = 0.047, Figure 1)
Summary
Prostate cancer (PCa) is the most common cancer in men (excluding non melanoma skin cancer) in the UK with over 40,000 cases diagnosed each year (CancerResearchUK 2015). For some men with early stage PCa that is confined to the prostate the disease may never be life threatening and can follow and indolent course which does not require urgent or invasive treatment. Prostate specific antigen levels (PSA), Gleason score and clinical and pathological grading used to diagnose and grade PCa lack the specificity or sensitivity to distinguish between patients with indolent PCa and those requiring radical treatment. Changes in PSA can precede clinical disease progression by months or years. The question of when to start therapy in PCa patients can be problematic. This poses a significant problem for clinicians when deciding the best treatment for their patients. There is, the clear need for a better understanding of the mechanisms involved in the development, progression
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
